No blended recommendations
A label and a professional guideline may differ. A different formulation or indication may only appear to conflict. Read the complete stored source, its date, renal measure, population and qualifications. These new interpretations remain pending independent clinical review.
Find a review question
Use drug/source terms only, never patient identifiers. Filters are in the URL. No JavaScript is required. CSV includes all matches, not just this page.
279 matching checks; page 24 of 28.
Source scope and renal guidance | Added v6.4
Before use: Sevelamer hydrochloride - RENAGEL tablets?
Sevelamer hydrochloride - RENAGEL tablets
Phosphorus concentration, meals and exact salt control these instructions. Carbonate and hydrochloride remain separate records; the adult switching instruction is not pediatric equivalence.
What to checkConfirm the salt, formulation, phosphate concentration, current binder, GI history and interacting medicines. Do not treat these rows as dialysis-clearance replacement doses.
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Scope and applicability | Added v5.3
Does the renal instruction belong to PAH or erectile dysfunction?
Sildenafil - REVATIO for pulmonary arterial hypertension
The selected REVATIO renal statement is a PAH instruction. The separate sildenafil record contains erectile-dysfunction material.
What to checkMatch indication and formulation; do not average starting-dose and no-adjustment instructions.
Related formulations / records - not interchangeable
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Qualitative precaution | Added v5.3
Are burn extent, systemic accumulation and source-specific monitoring being considered?
Silver sulfadiazine - SILVADENE 1% cream
The selected source describes impaired elimination and monitoring in extensive burns without a numerical renal reduction.
What to checkPreserve qualitative safety information instead of classifying missing numerical dosing as no renal concern.
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Qualitative sodium precaution | Added v5.6
Sodium burden matters without a clearance table?
Sodium phenylbutyrate - BUPHENYL tablets and powder
The source retains severe-renal and sodium-retention cautions without a numeric adjustment schedule.
What to checkReview sodium load and the metabolic-treatment plan; do not improvise a percentage reduction.
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Monitoring scope | Added v4.9
Does the source provide a dose change or only monitoring guidance?
Sodium phenylbutyrate - OLPRUVA oral suspension
The label supplies monitoring instructions but no numerical renal algorithm.
What to checkRetain ammonia and potassium surveillance. Do not substitute glycerol phenylbutyrate dosing.
Related formulations / records - not interchangeable
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Contraindication and fluid management | Added v5.9
A bowel-preparation renal contraindication is not a dose-reduction table?
Sodium picosulfate / magnesium oxide / citric acid - CLENPIQ oral solution
Both selected sources contraindicate severe renal impairment; the official precautions also address hydration and fluid intolerance.
What to checkDo not improvise a reduced preparation dose. Review fluid/electrolyte status and concomitant renal-risk medicines.
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Dialysis timing | Added v5.3
Are administration days and the potassium-sampling time both aligned with the chronic-HD source?
Sodium zirconium cyclosilicate - LOKELMA oral suspension
The selected dialysis regimen uses nondialysis-day administration and predialysis potassium after the long interval.
What to checkDo not substitute post-HD dosing or treat this schedule as emergency management of life-threatening hyperkalemia.
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Source scope difference | Added v5.3
Which exact product and recommended HCV regimen is being considered, and how is the product-label limitation addressed?
Sofosbuvir - SOVALDI in combination antiviral treatment
The retrieved SOVALDI label retains a severe-renal/ESRD limitation while the guideline discusses recommended sofosbuvir-containing regimens in these populations.
What to checkHave HCV pharmacy/specialist review the exact regimen and companion drugs. No blended dose is generated.
Related formulations / records - not interchangeable
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Guideline difference | Added v4.5
Is an old sofosbuvir restriction or a ribavirin rule being applied to the wrong regimen?
Sofosbuvir / velpatasvir - EPCLUSA
AASLD-IDSA records the 2019 regulatory change for sofosbuvir in severe kidney disease/dialysis. Its DAA no-adjustment recommendation does not apply automatically to ribavirin or resolve every liver/renal combined evidence gap.
What to checkDo not reuse a historical blanket severe-renal exclusion. Match the complete HCV regimen, hepatic status and any ribavirin requirement.
Related formulations / records - not interchangeable
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Scope and applicability | Added v5.3
Does the selected HCV regimen and hepatic status match VOSEVI rather than another sofosbuvir product?
Sofosbuvir / velpatasvir / voxilaprevir - VOSEVI tablets
The VOSEVI renal statement belongs to its three-drug combination, with separate hepatic and prior-treatment limitations.
What to checkDo not transfer it to every sofosbuvir product or disregard the combination-specific treatment criteria.
Related formulations / records - not interchangeable
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Before using a source
Confirm exact product and route, indication, age/weight, renal estimate and units, changing renal function, dialysis modality and timing, interacting medicines, monitoring, and the applicable institution's review. A successful page retrieval or a source-count badge establishes none of these on its own.
Clinician interpretation guideReturn to top